Description
Non-Invasive - anterior nasal swab specimens; no need to swab deep in the nasal cavity for sample collectionEasy to use - simple 4-step process from sample collection to resultsThis test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older or with adult-collected anterior nasal (nares) samples from individuals aged 2 years or olderThis test is authorized for individuals with symptoms of COVID-19 within the first 7 days of symptom onset when tested at least twice over three days with at least 48 hours between tests, and for individuals without symptoms or other epidemiological reasons to suspect COVID-19, when tested at least three times over five days with at least 48 hours between testsIndividuals should provide all results obtained with this product to their healthcare provider for public health reporting and to receive appropriate medical carePositive results indicate the presence of viral antigens, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection statusPositive results do not rule out bacterial infection or co-infection with other viruses and the agent detected may not be the definite cause of disease All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performedNegative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks; negative result should be considered in the context of an individual?s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19The Advin COVID-19 Antigen Test @ Home is a lateral flow immunoassay device intended for the qualitative detection of nucleocapsid protein antigens from SARS-CoV-2The Advin COVID-19 Antigen Test @Home is For FDA Emergency Use Authorization (EUA) only: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2Positive Percent Agreement (PPA) - 82.5% Negative Percent Agreement (NPA) - 100%
